title: Levamisole mucosal adjuvant activity for a live attenuated Escherichia coli oral vaccine in weaned pigs.
abstract: The present study tested the hypothesis that levamisole exerts its immunopotentiating activity in weaned pigs vaccinated against colibacillosis by priming the lymphocytes and macrophages in the mesenteric lymph node (MLN). Ten weaned piglets were used and allocated into two equal groups. The experimental group was intramuscularly primed with levamisole at an immunostimulatory dose of 2.5 mg/kg given daily, in three consecutive days, and controls received saline according to the same schedule. Both groups were orally vaccinated with the vaccinal Escherichia coli strain on day 0 and challenged with the virulent E. coli strain 7 days later. All pigs were killed on postchallenge day 6. Upon virulent challenge the health status of the two groups was evaluated by clinical observations, and expression of CD25, SWC7 and SWC9 activation antigens by MLN and spleen T and B cells and macrophages, respectively, was tested using flow cytometry. Priming by levamisole significantly contributed to the effectiveness of a live attenuated oral vaccine against porcine postweaning colibacillosis, as evidenced by a good health status of primed vaccinated vs. un-primed vaccinated pigs. The CD3+, CD25+ and SWC9+ MLN but not spleen T cells and macrophages increased in experimental vs. control pigs, implying that levamisole exerts its potentiating activity in the MLN by augmenting both recruitment and activation of cells that participate in cell-mediated immunity.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia. bozic@masef.vef.hr
authors.forename: F
authors.initials: F
authors.lastname: Bozić
authors.forename: V
authors.initials: V
authors.lastname: Bilić
authors.forename: I
authors.initials: I
authors.lastname: Valpotić
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D004357:Drug Synergism; D004926:Escherichia coli / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D022361:Escherichia coli Vaccines / Q000276:immunology* / Q000627:therapeutic use; D005434:Flow Cytometry / Q000662:veterinary; D018928:Immunity, Mucosal / Q000276:immunology; D007273:Injections, Intramuscular / Q000662:veterinary; D007978:Levamisole / Q000008:administration & dosage / Q000494:pharmacology*; D008198:Lymph Nodes / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects; D008643:Mesentery / Q000276:immunology / Q000382:microbiology; D013552:Swine; D013553:Swine Diseases / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated
chemical_list: D000276:Adjuvants, Immunologic; D022361:Escherichia coli Vaccines; D014613:Vaccines, Attenuated; D007978:Levamisole